GlassScriptPhysician profile
Christopher M Horn
NPI 1821095605
$8,910.90
in general payments reported to CMS, 2019-2025
44 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,581 · 2020: $462 · 2021: $537 · 2022: $1,336 · 2023: $1,700 · 2024: $1,753 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,995.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $989.57 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $987.00 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $845.03 | 2019-2025 | |
| Abbvie INC. | $835.49 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $820.44 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $733.76 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $596.61 | 2020-2025 | Rexulti |
| Glaxosmithkline, LLC. | $472.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $275.10 | 2019-2025 | Lagevrio, Dificid, Belsomra |
| Janssen Pharmaceuticals, INC | $263.32 | 2019-2025 | Spravato |
| Amgen INC. | $220.40 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $219.55 | 2019-2023 | Trintellix |
| Axsome Therapeutics, INC. | $168.68 | 2023-2025 | Auvelity |
| Teleflex LLC | $159.91 | 2024 | |
| Novartis Pharmaceuticals Corporation | $148.26 | 2019-2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.